Abstract

In order to explore the role of vitamins and paclitaxel on the proliferation of breast cancer cells and to provide a theoretical basis for clinical adjuvant therapy, 50 female patients with triple negative breast cancer were selected as the research subjects. These female patients were diagnosed in Zhoushan Maternal and Child Care Hospital from January 2015 to December 2018. They were then randomly divided into the study group and the control group, with 25 cases in each group. All patients were treated with gemcitabine and cisplatin chemotherapy. On this basis, the study group received adjuvant treatment of paclitaxel combined with vitamin C intravenous drip. According to the patient's medical records and follow-up records, the clinical efficacy, functional status scores, survival time and the level of tumor markers were counted and analyzed. The effect of paclitaxel combined with vitamin C on inhibiting the proliferation of cancer cells in cytological experiments was also investigated. The results showed that there was no significant difference in the treatment efficacy and clinical benefit rate between the two groups. The survival time without disease progression and the total survival time were compared between the two groups. The study group had significantly longer survival time than the control group (p<0.05). After the treatment, the Karnofsky performance status score of the study group was significantly higher than that of the control group (p<0.05). The incidence of side effects of nausea and vomiting, constipation, leukopenia, thrombocytopenia, anemia and abnormal liver function in the study group was significantly lower than that in the control group (p<0.05). The level of tumor markers after treatment was compared between the two groups and the difference was statistically significant (p<0.05). In addition, when paclitaxel was used in combination with vitamin C, the rate of cancer cell inhibition at any concentration was higher than that of paclitaxel and vitamin C alone. Paclitaxel and vitamin C adjuvant therapy for breast cancer could improve the efficiency of clinical treatment, prolong the survival time of patients and reduce the side effects of chemotherapy. In this study, cell experiments further confirmed that paclitaxel combined with vitamin C could inhibit the growth of breast cancer cells, and thus can be used as a theoretical basis for clinical medication.